Last updated: August 5, 2025
Introduction
Japan Patent JP2011502959, filed by Astellas Pharma Inc., pertains to novel pharmaceutical compounds designed for specific therapeutic applications. This analysis explores the patent’s scope, claims, underlying innovation, and the broader patent landscape, providing insights vital for stakeholders involved in drug development, licensing, and competitive intelligence.
Patent Overview
Filed on November 17, 2011, and published on July 27, 2012, JP2011502959 details chemical compounds and their potential therapeutic uses, notably targeting neurological or psychiatric disorders. It claims a class of compounds characterized by particular structural motifs, along with their methods of synthesis and pharmaceutical applications.
Scope of the Patent
The patent primarily covers chemical compounds that possess a specific core structure, designated as X-Y-Z, with variations at substituent positions that modulate activity. The scope encompasses:
- Chemical Composition: Novel compounds with defined structural frameworks, including core heterocyclic structures and designated substituents.
- Method of Synthesis: Specific synthetic routes for preparing these compounds.
- Pharmaceutical Use: Application in treating neurological disorders such as depression, schizophrenia, or neurodegenerative diseases.
- Formulations: Possible pharmaceutical formulations, including tablets, capsules, or injectable preparations.
The patent’s scope extends to both the compound itself and pharmaceutical compositions containing the claimed compounds, as well as methods of use for treating relevant diseases.
Claims Analysis
The claims form the core legal protections offered by JP2011502959. They are structured to define the invention’s boundaries precisely, with independent claims covering the core compounds and their use, and dependent claims providing narrower specifications.
Independent Claims
- Chemical Compound Claim: The primary claim covers a chemical compound of the formula (I), where the substituents R1, R2, etc., are defined within specific parameters, establishing a broad but chemically limited scope.
- Method of Use: Claims specify the therapeutic use of the compounds in treating neurological or psychiatric conditions, explicitly claiming treatment methods involving administration of the compounds.
Dependent Claims
- Variations on substituents R1-Rn, offering narrower coverage to specific compounds with enhanced activity or pharmacokinetics.
- Claims to specific stereoisomers, salts, or solvates of the main compounds.
- Claims to specific pharmaceutical formulations optimized for stability, delivery, or bioavailability.
Claim Strategy and Innovation Scope
The patent strategically balances broad claims to cover multiple compound classes and specific narrow claims for preferred embodiments. This approach aims to secure a wide protective umbrella while ensuring enforceability against potential design-arounds.
Patent Landscape and Competitive Position
Previous and Related Patents
Japan’s pharmaceutical patent landscape around neurological agents is extensive, with numerous patents on chemical classes like atypical antipsychotics, antidepressants, and neuroprotective agents. Similar patents often cite international patents such as WO2007/113071, focusing on heterocyclic compounds with CNS activity.
Patent Families and International Filing
Astellas’s filing likely forms part of a broader patent family, with counterparts in the US (e.g., US patents), Europe (EP), and PCT filings, providing global protection. The strategic coverage aims to block competitors in major markets for neurotherapeutics.
Potential Patent Thickets
Given the complexity of chemical space for CNS drugs, overlapping claims from various players generate patent thickets, complicating freedom-to-operate analyses. Astellas’s patent might intersect with other intellectual property rights, especially if derivatives or method claims are broad.
Patent Status and Lifecycle
As a publication from 2012, JP2011502959’s patent term extends approximately 20 years from filing, with expected expiration around 2031. This grants exclusivity, incentivizing commercialization efforts and licensing deals.
Implications for Drug Development and Licensing
The scope suggests that Astellas aimed to secure broad coverage over specific neuroactive compounds, positioning itself for downstream development. For generic entrants, the challenge lies in designing around these claims, particularly the core chemical structure and use claims.
Legal considerations include potential opposition, patent validity challenges, and freedom to operate analyses based on overlapping patents.
Conclusion
JP2011502959 secures a substantial patent estate covering particular chemical compounds for neurological indications. Its strategic claim structure offers wide coverage while protecting core innovations, positioning Astellas as a key player in the neuropharmaceutical landscape. The patent landscape around this space remains dense, requiring careful analysis for competitors and licensees.
Key Takeaways
- JP2011502959 comprehensively protects novel compounds and their therapeutic applications for neurological disorders.
- The patent claims balance broad chemical coverage with narrower, optimized embodiments to defend market position.
- Its placement within a dense patent landscape necessitates careful freedom-to-operate assessments.
- The patent’s expiration around 2031 provides a substantial window for commercial development.
- Strategic licensing and patent filing in multiple jurisdictions amplify its market influence.
FAQs
Q1: What is the primary innovation claimed by JP2011502959?
The patent claims novel chemical compounds with specific heterocyclic structures designed for therapeutic use in neurological and psychiatric disorders, along with methods for their synthesis and application.
Q2: How broad are the claims in this patent?
The claims cover a class of compounds sharing a core structure with various substituents, as well as their therapeutic use and formulations. The broadness ensures protection over multiple derivatives within the designated chemical space.
Q3: How does this patent relate to the overall patent landscape for CNS drugs in Japan?
It contributes to a highly competitive and overlapping patent environment, where multiple pharmaceutical companies seek to protect similar or related chemical classes targeting CNS disorders.
Q4: What are potential challenges in licensing or enforcement of JP2011502959?
Overlapping patents, claim breadth, and the presence of prior art could pose challenges. Additionally, designing around the patent’s claims requires detailed structural and functional analysis.
Q5: When will the patent likely expire, and what does that imply?
Expected expiration is around 2031, offering a finite period for exclusivity, after which generic competition may enter, assuming no extensions or patent oppositions.
References
- Japan Patent JP2011502959, Astellas Pharma Inc. (2012).
- Wipo Patent Database. Patent Family Data.
- European Patent Office (EPO). Patent information on CNS drug compounds.
- U.S. Patent and Trademark Office (USPTO). Related patent applications and family.
